Novel Therapeutic
Discovery Platform

New Cancer Specific Targets & Antibodies

New Hope in Cancer Therapy

Our Oncotope Platform rapidly identifies multiple cancer specific targets and simultaneously generates therapeutic antibodies against these targets.

NOVEL BREAST CANCER SURFACE ANTIGEN SLC39A7 (ZIP7) PRESENTED AT AACR 2024

Oncotope Antibody

ABOUT ONCOTOPE

  • Cancer is a global health emergency. Unfortunately, virtually all treatments that kill cancer cells adversely affect normal healthy cells, causing debilitating side effects.¬†
  • Targeted immunotherapy is the leading approach for combating cancer. A key challenge has been to identify cancer-specific antigens that are suitable for antibody-based therapeutics.
  • The market for cancer immunotherapies is substantial, exemplified by recent sales of two different antibodies¬†targeting a single antigen, TROP-2, on Triple Negative Breast Cancer, which reached a staggering $27 billion.
  • Our cutting-edge Oncotope Platform has revolutionized the discovery of cancer-specific antigens. Remarkably, it can identify multiple new antigens on any cancer type in a matter of months.

AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) 2024

AACR 2024 Poster Presentation

The novel breast cancer surface antigen SLC39A7 (ZIP7) was discovered by our team and presented at the American Association for Cancer Research (AACR) Annual Meeting on April 9, 2024.

ASCO PRESENTATION & PUBLICATION

Publication in the Journal of Clinical Oncology

An abstract embodying our novel method and research results was published by the American Society of Clinical Oncology (ASCO) on May 26, 2022.

ASCO 2022 Annual Meeting Poster Presentation

The results of our study were presented at the ASCO Annual Meeting in June 2022 with over 40,000 attendees.

VIDEO: ASCO 2022 Poster Presentation

ONCOTOPE PLATFORM PUBLICATION & PRESENTATION

An abstract embodying our novel method and research results was published by the American Society of Clinical Oncology (ASCO) on May 26, 2022. The results of our study were presented at the ASCO Annual Meeting in June 2022 with over 40,000 attendees.

Highlights of the abstract include: 

  • Antibodies generated against a specific type of cancer can kill those cancer cells without harming normal cells from the same tissue type and the same person.
  • These antibodies against one person’s cancer can kill the same cancer type from a different person.
  • These antibodies surprisingly can also kill cancer cells of a different type than the kind they were derived against.
  • Antibodies generated against one person’s cancer do not harm normal cells from a different person.
  • The platform can generate antibodies against a variety of cancers.